Insulet Corporation (PODD) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $148.33 (+0.25%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 15, 2026 | Richard Newitter | Truist Financial | $315.00 | +112.4% |
| Apr 14, 2026 | Shagun Singh | RBC Capital | $325.00 | +119.1% |
| Feb 19, 2026 | David Roman | Goldman Sachs | $326.00 | +119.8% |
| Feb 18, 2026 | William Plovanic | Canaccord Genuity | $435.00 | +193.3% |
| Jan 9, 2026 | Lee Hambright | Bernstein | $380.00 | +156.2% |
| Jan 9, 2026 | David Roman | Goldman Sachs | $365.00 | +146.1% |
| Nov 21, 2025 | Richard Newitter | Truist Financial | $412.00 | +177.8% |
| Nov 21, 2025 | Shagun Singh | RBC Capital | $380.00 | +156.2% |
| Nov 6, 2025 | Matthew Taylor | Jefferies | $400.00 | +169.7% |
| Nov 6, 2025 | Marie Thibault | BTIG | $370.00 | +149.4% |
| Nov 5, 2025 | Matt Miksic | Barclays | $301.00 | +102.9% |
| Nov 8, 2024 | Marie Thibault | BTIG | $270.00 | +82.0% |
| Nov 5, 2024 | Lee Hambright | Bernstein | $300.00 | +102.3% |
| Oct 14, 2024 | Jayson Bedford | Raymond James | $260.00 | +75.3% |
| Sep 17, 2024 | Matt O'Brien | Piper Sandler | $285.00 | +92.1% |
| Aug 27, 2024 | Matt O'Brien | Piper Sandler | $230.00 | +55.1% |
| Aug 27, 2024 | Steven Lichtman | Oppenheimer | $233.00 | +57.1% |
| Aug 27, 2024 | Matthew Taylor | Jefferies | $260.00 | +75.3% |
| Aug 9, 2024 | Marie Thibault | BTIG | $250.00 | +68.5% |
| May 13, 2024 | Matt Miksic | Barclays | $200.00 | +34.8% |
Top Analysts Covering PODD
PODD vs Sector & Market
| Metric | PODD | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.23 | 2.24 | 2.40 |
| Analyst Count | 35 | 8 | 19 |
| Target Upside | +49.1% | +11475.0% | +17.1% |
| P/E Ratio | 34.50 | 3.88 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.29B | $3.31B | $3.32B | 18 |
| 2027-12-31 | $3.67B | $3.96B | $4.03B | 18 |
| 2028-03-31 | $1.02B | $1.04B | $1.06B | 6 |
| 2028-06-30 | $1.10B | $1.12B | $1.15B | 6 |
| 2028-09-30 | $1.19B | $1.21B | $1.24B | 11 |
| 2028-12-31 | $1.29B | $1.31B | $1.34B | 6 |
| 2029-03-31 | $1.22B | $1.24B | $1.27B | 7 |
| 2029-06-30 | $1.32B | $1.34B | $1.38B | 10 |
| 2029-09-30 | $1.44B | $1.47B | $1.50B | 7 |
| 2029-12-31 | $1.59B | $1.62B | $1.66B | 9 |
| 2030-12-31 | $5.88B | $6.14B | $6.26B | 15 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $5.36 | $6.35 | $6.60 | 14 |
| 2027-12-31 | $6.00 | $8.13 | $8.79 | 14 |
| 2028-03-31 | $1.86 | $1.90 | $1.96 | 6 |
| 2028-06-30 | $2.18 | $2.23 | $2.30 | 6 |
| 2028-09-30 | $2.60 | $2.66 | $2.75 | 7 |
| 2028-12-31 | $3.17 | $3.24 | $3.35 | 9 |
| 2029-03-31 | $2.22 | $2.27 | $2.35 | 8 |
| 2029-06-30 | $2.75 | $2.81 | $2.91 | 8 |
| 2029-09-30 | $3.33 | $3.40 | $3.52 | 9 |
| 2029-12-31 | $3.87 | $3.95 | $4.08 | 11 |
| 2030-12-31 | $13.74 | $14.53 | $14.88 | 6 |
Frequently Asked Questions
What is the analyst consensus for PODD?
The consensus among 35 analysts covering Insulet Corporation (PODD) is Buy with an average price target of $357.25.
What is the highest price target for PODD?
The highest price target for PODD is $435.00, set by William Plovanic at Canaccord Genuity on 2026-02-18.
What is the lowest price target for PODD?
The lowest price target for PODD is $200.00, set by Mike Polark at Wolfe Research on 2024-05-07.
How many analysts cover PODD?
35 analysts have issued ratings for Insulet Corporation in the past 12 months.
Is PODD a buy or sell right now?
Based on 35 analyst ratings, PODD has a consensus rating of Buy (2.23/5) with a +49.1% upside to the consensus target of $357.25.
What are the earnings estimates for PODD?
Analysts estimate PODD will report EPS of $6.35 for the period ending 2026-12-31, with revenue estimated at $3.31B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.